Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: Hypertension
Interventions: Minocycline Group, Placebo Group; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Increased Drug Resistance
Interventions: Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Epilepsy
Interventions: Cannabidiol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Intractable Epilepsy
Interventions: stimulating probes and electrodes; Device
Lead sponsor: University of Michigan; Other
Eligibility: 22 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Interventions: Carbon-14-labeled carboplatin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Sacramento, California

Conditions: Obesity
Interventions: Metformin, Dietary modification with caloric restriction, Establishment of exercise protocol; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Interventions: UB-421; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multi-drug Resistant Gram-negative Bacilli Colonization
Interventions: MDR-GNB; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hospitalization, Infection
Interventions: Chlorhexidine gluconate (CHG), Iodophor (10% povidone-iodine); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 13,952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 28
States / cities: Anaheim, California • Bellflower, California • Capistrano Beach, California + 9 more

Conditions: Drug Resistant Epilepsy
Interventions: Survey questionnaires, Epilepsy Visit Planner, Questionnaires for Providers; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Drug-resistant Epilepsy
Interventions: Stereoelectroencephalography; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Dietary supplement for weight loss, Education and counseling for weight loss; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Obsessive-Compulsive Disorder
Interventions: dextro-amphetamine, Sham Comparison; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Intestinal Multi-drug Resistant Organism Colonization
Interventions: Microbiome Therapeutic, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Resistant Hypertension
Interventions: HyperQureTM Renal Denervation (RDN) System:; Device
Lead sponsor: DeepQure Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Orange, California • Stanford, California • Gainesville, Florida + 3 more

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: abiraterone acetate, dietary intervention, pharmacological study, questionnaire administration, laboratory biomarker analysis; Drug · Dietary Supplement · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 2 Diabetes
Interventions: Acipimox, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: aripiprazole (Abilify), ziprasidone (Geodon); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infections, Chronic Hepatitis B
Interventions: Adefovir Dipivoxil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: FG-3246; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma of the Lung, Lung Cancer, Squamous Cell Lung Cancer
Interventions: Docetaxel, Nivolumab, Gemcitabine, Pemetrexed; Drug
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Anderson, Indiana • Indianapolis, Indiana • Muncie, Indiana + 4 more

Conditions: Unipolar Depression
Interventions: lamotrigine, placebo, paroxetine; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pre-Diabetes, Metabolic Syndrome, Type 2 Diabetes
Interventions: Lifestyle intervention and provider feedback; Behavioral
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy

Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

Goals for Epilepsy Clinic Visits Trial

Electrophysiologic Studies of Cognition in Epilepsy Patients

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

Further MT for Antibiotic-Resistant Bacterial Colonization

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Lamotrigine Augmentation in Resistant Depression

Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care